Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Polyrizon Ltd. ( (PLRZ) ) has shared an update.
On May 4, 2026, Polyrizon Ltd. announced that it has submitted amended claims in its U.S. patent application covering its proprietary intranasal drug delivery platform, expanding protection beyond the core mucoadhesive composition. The new claims cover drug delivery systems and methods of use designed to increase residence time and ensure close contact with mucosal tissues, aligning with the company’s strategy to strengthen its global intellectual property position.
The expanded U.S. claims relate to sulfated polysaccharide-based compositions that form a uniform, continuous film on epithelial mucosa, supporting prolonged residence time, improved bioavailability, and compatibility with a broad range of drug types and indications. This move underscores Polyrizon’s bid to enhance the value and versatility of its intranasal technology platform, potentially improving treatment outcomes and reinforcing its competitive footing in intranasal drug delivery and barrier protection solutions.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development-stage biotech company focused on innovative intranasal hydrogels delivered as nasal sprays, aimed at forming a thin hydrogel-based barrier in the nasal cavity to block viruses and allergens from contacting nasal epithelial tissue. Its proprietary Capture and Contain hydrogel technology, and earlier-stage Trap and Target platform, target both protective barrier functions and intranasal delivery of active pharmaceutical ingredients for local and systemic therapies.
The company’s products are positioned at the intersection of medical devices and drug delivery, leveraging mucoadhesive and prolonged-retention properties to improve residence time and bioavailability for a wide range of therapeutic indications. Based in Raanana, Israel and listed on Nasdaq under the ticker PLRZ, Polyrizon is building a global intellectual property portfolio around these intranasal delivery and barrier technologies.
Average Trading Volume: 45,803
Technical Sentiment Signal: Hold
Current Market Cap: $28.53M
For a thorough assessment of PLRZ stock, go to TipRanks’ Stock Analysis page.